MIME-Version: 1.0 Content-Type: multipart/related; boundary="----=_NextPart_01C701B1.8F8BEE20" This document is a Single File Web Page, also known as a Web Archive file. If you are seeing this message, your browser or editor doesn't support Web Archive files. Please download a browser that supports Web Archive, such as Microsoft Internet Explorer. ------=_NextPart_01C701B1.8F8BEE20 Content-Location: file:///C:/CB2C5625/2005AGMminutesMelbourne.htm Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii" DRAFT

Minu= tes of Annual General Meetings (AGMs)
held in Melbourne, = Australia

Sund= ay 23 October 2005

 

[These minutes were approved on 25 October 2006.]

Present: Entity representatives, Steering Group members, Collaboration Trading Company Directors, and Secret= ariat staff (see Appendix 1 for the list of those who were present, and those who= had sent their apologies).

  1. Welcomes, apologies for absence, and approval of the agenda

Mark Davies welcomed everyone to the AGMs, and explained their purpose. He thanked Mike Clarke, Prathap Tharyan and Pisake Lumbiganon for their presentation about the Collaboration’s response to the tsunami before the commencement of the AGMs. The agenda was approved.

  1. Steering Group membership

Mark explained that a proportion of the members of The Cochrane Collaboration Steering Group (CCS= G) changes each year. He thanked Jim Neilson and Davina Ghersi as they were now leaving the CCSG; they had both been members for six years, Jim as Co-ordinating Editor representative and then as Co-Chair, and Davina as Rev= iew Group Co-ordinator/Trials Search Co-ordinator (RGC/TSC) representative. Mark introduced the incoming new members: Donna Gillies (representing authors), Adrian Grant (representing Co-ordinating Editors), Narelle Willis (represen= ting RGCs and TSCs), and Hans van der Wouden (representing members of Cochrane Review Groups (CRGs)).

Mike Clarke took over as Chair of the meeting for agenda items 3 to 8. He explained the importance of these AGMs, including the need to satisfy the legal requirements governing charities registered in England and Wales.

 

  1. Approval of minutes of the Annual General Meetings of The Cochr= ane Collaboration and the Collaboration Trading Company Limited held on 3 October 2004

Mike asked for comments= or corrections for the minutes: there were none. Steff Lewis proposed and Rob Scholten seconded approval of the minutes.

  1. Annual Report to Companies House

Mike reminded entity representatives that they had been sent the Annual Report for the year April 2004 to March 2005 on 30 September 2005. He asked for any comments or questions: there were none. Jordi Pardo proposed the approval of the Annual Report to Companies House, Janet Wale seconded the proposal, and the motion= was carried.

  1. Financial statements for the year to 31 March 2005 <= /span>

Mike reminded entity representatives that they had been sent the financial statements for the ye= ar April 2004 to March 2005 on 30 September 2005. He asked for any comments or questions: there were none. Davina Ghersi proposed approval of these financ= ial statements; Lisa Bero seconded the proposal, and the motion was carried.

  1. Reappointment of auditors, Mazars LLP

Mike explained that each year the AGMs need to appoint a firm of accountants; the Trading Company Directors and the members of the Steering Group had agreed that the present accountants should be reappointed. He asked for comments or questions: there were none. Jon Deeks proposed that Mazars LLP be reappointed, Hans van der Wouden seconded the proposal, and the motion was carried. Jini Hetherington= was requested to let Mazars LLP know of this decision.
Action: Jini Hetherington

  1. Approval of accounting policies

Mike explained the requirement to approve the current accounting policies. He asked for commen= ts or questions: there were none. Godwin Aja proposed that they be approved, P= eter Tugwell seconded the proposal, and the motion was carried. Jini Hetherington was asked to let Mazars LLP know of this.
Action: Jini Hetherington

  1. Reappointment of Trading Company Director=

Mike explained that one= of the three Trading Company Directors (Monica Kjeldstrøm, Peter Langho= rne or himself) was required to resign each year and could be reappointed if th= ey were willing. Monica stepped down, and Mike proposed that she be reappointe= d; this was seconded by Liz Waters, and carried.

  1. Amendments to the Memorandum and Articles of Association

Mark Davies resumed the position of Chair for the rest of the meeting. He reminded everyone that the Memorandum and Articles of Association of The Cochrane Collaboration had be= en approved at the previous AGM in October 2004, and were available on the Collaboration website. He explained that the Charity’s objects remain= ed unchanged, namely, “the protection and preservation of public health through the preparation, maintenance and dissemination of systematic review= s of the effects of health care, for the public benefit.” This concluded t= he formal part of the AGMs.

  1. Any other business:

 

10.1  Collaboration finances: Jon= Deeks made a brief presentation about the Collaboration’s finances in his r= ole as Treasurer. He showed several graphs indicating the historical trends and current state of the organisation’s finances as of March 2005. Sales income from The Cochrane Library had been increasing year on year, as had the royalty percentage which determined the Collaboration’s share. Wiley had projected sales income for the current year approaching 1,700,000 pounds sterling, and the Collaboration’s royalty rate was now at forty per cent. In the past five years the Collaboration had built up a surp= lus of funds, which had started to be reduced during the past two years as the Collaboration committed more expenditure than its likely income. A reserve level of funds had been identified which the Steering Group aimed to mainta= in for contingency purposes year on year. In the past year the main items of expenditure had been on Secretariat running costs; the Information Manageme= nt System; development of the Collaboration’s website; sponsored entity registration fees for Colloquia; complementary subscriptions to The Coch= rane Library for all entities; Steering Group, sub- and advisory group runni= ng costs; and development of the processes for preparing reviews of diagnostic test accuracy.

10.2          ISI and impact factors: Mark Davies explained that the Instit= ute for Scientific Information (ISI) had evaluated The Cochrane Database of Systematic Reviews (CDSR) = and that CDSR had passed its techni= cal evaluation in May 2005. ISI had therefore accepted CDSR for listing and would cover all new and updated Cochrane r= eviews from Issue 1, 2005. The first impact factor for CDSR would be released in June 2008. It would be a measure of citations in 2007 to articles published in 2005 and 2006. Mark stressed the importance of the accuracy of citations to Cochrane reviews. He congratulat= ed Wiley who had been working diligently towards this end; they had provided a list of Frequently Asked Questions about this to Colloquium participants. Reviews in CDSR would also be included on the ISI Web of Science in the Science Citation Index Expanded and in Current Contents/ Clinical Medicine databases; all of this was increasing accessibi= lity to Cochrane reviews.

10.3=      Sustainability an= d The Cochrane Collaboration: Mike Clarke presented an item = on behalf of Ian Roberts, Co-ordinating Editor of the Cochrane Injuries Group, relating to carbon emissions. Mike explained that Ian, who was not at the Colloquium, had asked him to read out a statement on his behalf, and that he had agreed to do so as Director of the reference Cochrane Centre for the Cochrane Injuries Group. He read an abridged version of Ian’s stateme= nt, and said that a copy of the full statement would be attached to the minutes= of this meeting (see Appendix 2). One of the recommendations in Ian’s statement was the establishment of a working group within the Collaboration. Sally Green said she recognised the importance of this issue, but pointed o= ut that reducing travel would impact far more highly on Australia than elsewhere and = she would be very disappointed to see the Collaboration reduce the amount of international travel for this reason. Ron Koretz asked whether there were d= ata to support Ian Roberts’ recommendations, but Ian had not provided any. Mark explained that the Steering Group had discussed this matter and referr= ed it to the Colloquium Policy Advisory Group (CPAG) to discuss and report bac= k to the Steering Group, as adopting Ian’s recommendations would have a ma= jor impact on future Colloquia. Andrew Herxheimer said there should be a mechan= ism for keeping this issue in mind and returning to it when the data have been properly discussed and investigated. He said there might be a way of feeding this factor into decisions about the location of future Colloquia. He suppo= rted Ian Roberts putting this up for discussion and keeping it on the agenda. Ja= net Hiller said that in = Australia one could choose green options at a personal level which enabled people to contribute as individual members rather than changing the way the Collabora= tion meets. Miranda Cumpston of the Canadian Cochrane Centre said that climate change is a health intervention of a kind; environmental changes might affe= ct health, and is already having an impact.

There were no further items of business, and the meeting ended after one ho= ur.

 

Appendix = 1 


Entities (members) of The Cochrane Collaboration

 

Entity

 

Represented by <= o:p>

 

Collaborative Review Groups (50):

 

1.  Airways Group

Elizabeth Arnold

2.  Anaesthesia Group

Nete Villebro

3.  Acute Respiratory Infections Gro= up

Liz Dooley

4.  Back Group

Victoria Pennick

5.  Bone, Joint and Muscle Trauma Gr= oup

Bill Gillespie

6.  Breast Cancer Group

Sharon Parker

7.  Colorectal Cancer Group

Henning Andersen

8.  Consumers & Communication Group       &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;      

Megan Prictor

9.  Cystic Fibrosis and Genetic Diso= rders Group

Nikki Jahnke

10.  Dementia and Cognitive Improveme= nt Group

Dymphna Hermans

11. Depression, Anxiety and Neurosis Group

Rachel Churchill

12. Developmental, Psychosocial and Learning Problems Group

Jane Dennis

13. Drugs and Alcohol Group=

Apologies

14. Ear, Nose and Throat Disorders Group=

Martin Burton

15. Epilepsy Group

Rachael Jowett

16. Effective Practice and Organisation of Care Group

Alain Mayhew

17. Eyes and Vision Group       &nbs= p;            &= nbsp;           &nbs= p;             &nbs= p;            &= nbsp;           &nbs= p;   

Richard Wormald

18. Fertility Regulation=

Metin Gülmezoglu

19. Gynaecological Cancer Group=

Clare Jess

20. Haematological Malignancies Group       &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;      

Thilo Kober

21. Heart Group

William Hood

22. Hepato-Biliary Group=

Christian Gluud

23. HIV/AIDS Group

Joy Oliver

24. Hypertension Group

Ciprian Jauca

25. Incontinence Group       &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;       

June Cody

26. Infectious Diseases Group=

Reive Robb

27. Inflammatory Bowel Disease Group       &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;     

Apologies

28. Injuries Group

Katharine Ker

29. Lung Cancer Group

Sera Tort

30. Menstrual Disorders and Subfertility Group

Cindy Farquhar

31. Metabolic and Endocrine Disorders Group

Susanne Ebrahim

32. Methodology Review Group=

Elizabeth Paulsen

33. Movement Disorders Group       &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;           &nbs= p;      

Apologies

34. Multiple Sclerosis Group       &nbs= p;          &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;           &nbs= p;

Graziella Filippini

35. Musculoskeletal Group=

Lara Maxwell

36. Neonatal Group

Roger Soll

37. Neuromuscular Disease Group       &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;           &nbs= p;  

Kate Jewitt

38. Oral Health Group

Emma Tavender

39. Pain, Palliative and Supportive Care Group

Jessica Thomas

40. Pregnancy and Childbirth Group       &nbs= p;            &= nbsp;           &nbs= p;       

Sonja Henderson

41. Prostatic Diseases and Urologic Cancers Group       &nbs= p;            &nbs= p;            &= nbsp;           &nbs= p;  

Apologies

42. Peripheral Vascular Diseases Group=

Heather Maxwell

43. Renal Group

Jonathan Craig

44. Schizophrenia Group       &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;     

Mark Fenton

45. Sexually Transmitted Diseases Group       &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;    

George Schmid

46. Skin Group

Tina Leonard

47. Stroke Group

Apologies

48. Tobacco Addiction Group       &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;           &nbs= p;        

Apologies

49. Upper Gastrointestinal and Pancreatic Diseases Group       &nbs= p;            &= nbsp;  

Iris Gordon

50. Wounds Group

Nicky Cullum

 

 

Fields/Networks (11):

 

1.  Cancer Network

Mark Lodge

2.  Child Health Field       &nbs= p;            &= nbsp;           &nbs= p;                   &nbs= p;            &= nbsp;           &nbs= p;     

Denise Thomson

3.  Complementary Medicine Field       &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;           &nbs= p;   

Eric Manheimer

4.  Health Care of Older People Fiel= d       &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;            

Gilbert Ramirez

5.  Health Promotion and Public Heal= th Field

Rebecca Armstrong

6.  Neurological Network       &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;     

Livia Candelise

7.  Occupational Health       &nbs= p;            &= nbsp;             &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;          

Jos Verbeek

8.  Pre-hospital and Emergency Health Field       &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;       

Apologies

9.  Primary Health Care Field       &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;         &nbs= p;            &= nbsp; 

Glenn Griffin

10. Rehabilitation and Related Therapies Field

Marijke Moll

11. Vaccines Field       &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;           &nbs= p;  

Apologies

 

 

 Consumer Network       &nbs= p;                    &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;           &nbs= p;    

Liz Whamond

 

 

Methods Groups (11):

 

1.  Applicability and Recommendations Methods Group

Apologies

2.  Economics Methods Group       &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;           &nbs= p;         <= span lang=3DEN-GB style=3D'font-size:9.0pt;font-family:Arial;mso-fareast-font-= family: "Arial Unicode MS"'>

Apologies

3.  Individual Patient Data Methods = Group

Lesley Stewart

4.  Information Retrieval Methods Gr= oup

Carol Lefebvre

5.  Non-Randomised Studies Methods G= roup

Barney Reeves

6. Patient Reported Outcomes Methods Group

Donald Patrick

7.  Prospective Meta-Analysis Methods Group

Nicole Holcroft

8.  Qualitative Research Methods Group       &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;     

Apologies

9.  Reporting Bias Methods Group

Jonathan Sterne

10.  Screening and Diagnostic Tests M= ethods Group             &nbs= p;            &= nbsp;        

Petra Macaskill<= /o:p>

11. Statistical Methods Group

Doug Altman

 

 

Centres (12)

 

1. Australasian Cochrane Centre

Denise O’Connor

2. Brazilian Cochrane Centre

Alvaro Atallah

3. Canadian Cochrane Centre

Jeremy Grimshaw

4. Chinese Cochrane Centre

Youping Li

5. Dutch Cochrane Centre  =

Mariska Leeflang

6. German Cochrane Centre       &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;           &nbs= p;           

Gerd Antes

7. Iberoamerican Cochrane Centre

Xavier Bonfill

8. Italian Cochrane Centre

Alessandro Liberati

9. Nordic Cochrane Centre

Peter Gøtzsche

10. South African Cochrane Centre

Elizabeth Pienaar

11. UK Cochrane Centre

Caroline Rouse

12. US Cochrane Center

Kay Dickersin

 

 

Total number of entities:  85

 

&n= bsp;

= Steering Group members

Godwin Aja

Lorne Becker

Lisa Bero

Mark Davies

Jon Deeks

Zbys Fedorowicz

Davina Ghersi (outgoing member)=

Donna Gillies

Adrian Grant

Sally Green

Steff Lewis

Jim Neilson (outgoing member)

Jordi Pardo

Rob Scholten

Peter Tugwell

Janet Wale

Liz Waters

Narelle Willis

Hans van der Wouden

 

Collaboration Tr= ading Company Directors

Mike Clarke
Monica Kjeldstrøm

Peter Langhorne &= nbsp;           &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;           &nbs= p;            &= nbsp;  Apologies

 

Secretariat staf= f

Claire Allen

Jini Hetherington (minutes)

Nick Royle

Diana Wyatt

Appe= ndix 2

 

Sta= tement on sustainability
by Ian Roberts (Co-ordinating Editor, Cochrane Injuries Group),
to be read out at the AGM of The Cochrane Collaboration
on 23 October 2005 in Melbourne, Australia

 

I am grateful for the opportunity to address this meeting in absentia and to highlight the need for urgent actions to reduce the emissions of greenhouse gases arising from the activities of The Cochrane Collaboration.

 

The UN Intergovernmental Panel on Climate Change has reviewed the available scientific evidence and has concluded that we are now in a period of rapidly changing global climate, driven mainly by the emissions of greenhouse gases resulting from the burning of fossil fuels. Current projections are for an increase in global temperatures of around 1.5 to 6.0 degrees Celsius over t= his century. This is a faster rate of change than at any time since the incepti= on of agriculture 13,000 years ago. The rate and extent of warming is likely to have serious consequences for ecosystems and human populations in many regi= ons. The WHO estimates that more than 150,000 people in developing countries are already dying each year from the effects of global warming.

 

The Cochrane Collaboration, like all organizations, must acknowledge the threat posed by climate change and take action to reduce the emissions associated = with its activities. How carbon dioxide reductions might equitably be achieved i= s an issue for debate.  However, it= seems likely that agreement would have to be based on the principles of Contracti= on and Convergence proposed by the Global Commons Institute. These principles = are that global emissions of carbon dioxide must be reduced to an international= ly agreed level (contraction); and that global governance must be based on jus= tice and fairness with convergence to equal per capita carbon emission shares. Equitable stabilization scenarios have m= ajor implications for high income countries, which are required to begin immedia= te and progressive reductions in energy use. Under Contraction and Convergence, the achievement of 550 ppm stabilization would require a reduction in yearly emissions for the average UK citizen from about 5.2 tonnes per person per y= ear to 2.0 tonnes by 2050; it would require reduction to just over 1 tonne per person per year if the aim is the more stringent target of 450 ppm which ma= ny believe necessary. To set these reductions in context, a round trip by air = to Melbourne from Northern Europe corresponds to about 11 tons of carbon dioxi= de per person.

 

I propose the establishment of= a standing group of The Cochrane Collaboration charged with the task of promo= ting the necessary year on year reductions in CO2 emissions associated with the Collaboration’s activities. I am confident that the Collaboration will take this issue seriously. In a period when politicians = have promoted lies, the Collaboration has championed truth and the avoidance of bias. In a time of unprecedented international conflict, The Cochrane Collaboration has championed international co-operation and inclusiveness. = Now facing the prospects of global climate chaos, I have no doubt that the Collaboration will embrace sustainability. Thank you.

 

------=_NextPart_01C701B1.8F8BEE20 Content-Location: file:///C:/CB2C5625/2005AGMminutesMelbourne_files/header.htm Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

30 O= ctober 2006

------=_NextPart_01C701B1.8F8BEE20 Content-Location: file:///C:/CB2C5625/2005AGMminutesMelbourne_files/filelist.xml Content-Transfer-Encoding: quoted-printable Content-Type: text/xml; charset="utf-8" ------=_NextPart_01C701B1.8F8BEE20--